Cas:46322-66-1 2-[(E)-(2,4-dichlorophenyl)methylideneamino]guanidine manufacturer & supplier

We serve Chemical Name:2-[(E)-(2,4-dichlorophenyl)methylideneamino]guanidine CAS:46322-66-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2-[(E)-(2,4-dichlorophenyl)methylideneamino]guanidine

Chemical Name:2-[(E)-(2,4-dichlorophenyl)methylideneamino]guanidine
CAS.NO:46322-66-1
Synonyms:2,4-Dichlor-benzaldehyd-guanylhydrazon;2,4-dichlorobenzaldehyde guanylhydrazone
Molecular Formula:C8H8Cl2N4
Molecular Weight:231.08200
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:396.7ºC at 760mmHg
Density:1.49g/cm3
Index of Refraction:1.645
PSA:74.26000
Exact Mass:230.01300
LogP:3.00130

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 2,4-Dichlor-benzaldehyd-guanylhydrazon chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,4-dichlorobenzaldehyde guanylhydrazone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,4-Dichlor-benzaldehyd-guanylhydrazon Use and application,2,4-Dichlor-benzaldehyd-guanylhydrazon technical grade,usp/ep/jp grade.


Related News: Now that Alexion’s Soliris is in AstraZeneca’s hands, the drugmaker is counting on the C5 inhibitor to help push it toward billions in sales in just a few years. But a prominent drug pricing watchdog is raising a red flag over its costs for patients with a rare neuromuscular disorder. 9-benzhydryloxy-7-(4-fluoro-benzyl)-8-oxo-7,8-dihydro-6H-pyrrolo[3,4-g]quinoline-5-carboxylic acid manufacturers Our COVID-19 vaccine, Vaxzevria, undergoes extremely robust safety and quality testing prior to becoming available for patients. 2,3-diphenyl-6-undecylimidazo[2′,1′:2,3]thiazolo[5,4-a]phenazin-5(7H)-one suppliers TULIP-2 assessed the effect of anifrolumab in reducing disease activity as measured by the BILAG-Based Composite Lupus Assessment (BICLA) scale. In TULIP-1, 457 eligible patients were randomised (1:2:2) and received a fixed-dose intravenous infusion of 150mg anifrolumab, 300mg anifrolumab or placebo every four weeks, 7-methyl-5-nitro-quinoxaline vendor & factory.